This site provides INTERCEPT product information for Health Care Professionals in the United States. Learn more

Cerus Websites
INTERCEPT PLATELETS

Improves Availability

Faster Availability with INTERCEPT® Platelets

Earlier release of platelets treated with the INTERCEPT Blood System Pathogen Reduction System (INTERCEPT Platelets) may translate to sooner availability, improved shelf-life, and transfusion of fresher platelets when compared to tested/cultured platelets.1,2

READ THE CASE STUDIES

Impact of Pathogen Reduction vs Large Volume Delayed Sampling Testing on Platelet Availability

Comparing Usable Shelf-life of Pathogen Reduction Platelets vs Large Volume Delayed Sampling Screened Platelets

Distribution of platelet age at time of transfusion when comparing INTERCEPT Platelets to LVDS tested platelets.1

“INTERCEPT Platelets are a valuable enhancement to our blood supply. In addition to the increased confidence in the safety of the platelet supply, pathogen reduced INTERCEPT Platelets have given our center the flexibility to release platelet units on day 1, which has been essential during critical platelet shortages.”

Alyssa Ziman, MD

Medical Director, Transfusion Services
UCLA

A proactive approach to pandemic preparedness

As new pathogens emerge, a reactive approach, like testing, may not be sustainable as test development and regulatory approvals take time. INTERCEPT Platelets offer a proactive approach to pandemic preparedness through the inactivation of certain emerging pathogens3 and have helped sustain platelet availability during outbreaks.4,5

“Pathogen Reduction has been acknowledged by international experts6 as a method to protect the blood supply during the different phases of a pandemic as defined by the WHO.7 It should be considered as part of pandemic preparedness.”

Dr. Maria De Los Angeles Muñiz

Pathologist
Robert Wood Johnson University Hospital

You  may also be interested in View all 

Why Blood Safety Matters
Preparing Our Blood Supply for the Next Pandemic with Dr. Susan Stramer
Listen now
Elevate Patient Care
Evaluating Usable Shelf-Life of Pathogen Reduced and LVDS Tested Platelets
Watch now
Mechanism of Action
Why INTERCEPT: Platelet Availability
Read more

References:

  1. Collier, T., and Chrebtow, V. “Impact of Pathogen Reduction (PR) vs LVDS Testing on Platelet Availability: A Study Based on Real-World Experience.” AABB 2022. Poster P-IV-8.
  2. Prichard, A.B., et al. “Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs LVDS Screened Platelets.” AABB 2022. Poster P-IV-2.
  3. The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation.
  4. Allain, J.P., et al., Transfus Med Rev, 2005. 19(2): p. 110-26.
  5. Rasongles P, et al. Transfusion 2009; 49: 1083-91.
  6. Strengers, et al.Vox Sang.2023; 118: 8– 15.31.
  7. “Guidance on Ensuring A Sufficient Supply of Safe Blood and Blood Components During Emergencies,” WHO, 2023.